Background
Multiple Sclerosis (MS) is a chronic infl ammatory demyelinating disease believed to be mediated by autoreactive lymphocytes that invade the Central Nervous System (CNS) causing damage to oligodendrocytes and axons and resulting in demyelination, neuronal death and brain atrophy. (1) In the more common relapsing form of disease, onset is typically heralded by the acute onset of neurological symptoms and signs that usually resolve spontaneously or more quickly in response to high dose steroids. Subsequently this phase of illness is characterized by relapses and remissions that are believed to be due to repeated infl ammatory attacks on the CNS, as demonstrated by the appearance of new or enhancing lesions on MRI studies and characterized pathologically by T cell-dominated perivenular infi ltrates. Eventually, the amassed damage overcomes the ability of the CNS to repair or divert neurological pathways and patients start to become signifi cantly disabled. This subsequent secondary progressive phase is characterized by a change in the quality of the infl ammatory response detected within the CNS which becomes more diffuse and macrophage/microglia dominated. Current treatments, which act more as immunomodulators, are effective at altering the natural course of disease by targeting mainly the early phase of infl ammation, but virtually all have failed to halt the build-up of disability when used in the later secondary progressive phase of disease. It is clear that when immunomodulation starts to fail to contain relapses and MRI activity, immunosuppressive agents still seem to be effective. Cyclophosphamide was used for years to control this phase of disease, but studies have failed to demonstrate statistical signifi cance. While mitoxantrone has been shown to more defi nitively effective, toxicity, especially the increased incidence of leukaemia, has dampened enthusiasm and limited its usefulness. More recent immunomodulators have been shown to be effective at containing advancing disease, but agents such as natalizumab are increasingly associated with intolerable toxicity such as the development of PML or cerebral lymphoma. On the horizon are other agents, all aimed at the early infl ammatory phase of illness (e.g. cladribrine, alemtuzumab, fi ngolimod, terifl unomide), and at least two of these (cladribine and alemtuzumab) have failed to have any effect on the secondary progressive phase. Because of the concern regarding the toxicity associated with prolonged immunosuppression, immunomodulation or reduced immunosurveillance associated with all of the above agents to date, there may be a role for a single complete hit to the immune system, that in one fell swoop will destroy ongoing infl ammation, restore tolerance and avoid the need for continued treatment with either immunomodulators or immunosuppressive drugs. Such a goal can be obtained with intensive immunosuppression and autologous stem cell transplantation. Autologous Haematopoietic Stem Cell Transplantation (AHSCT) has been used experimentally for the last twelve years for treatment of MS patients who deteriorate despite administration of approved treatments. Most patients have been included in small phase 1-2 trials and currently no data are available from prospective comparative trials. In 2004, the European Blood and Marrow Transplantation Group (EBMT, www.ebmt.org) launched a prospective phase 2 trial (ASTIMS, www.astims.org) comparing AHSCT vs Mitoxantrone, with a MRI endpoint (number of new T2 lesions at 1 and 2 years after the randomization). The accrual of the trial was disappointing due to a number of reasons such as: stringent selection criteria, previous treatment with Mitoxantrone, lack of funding and, more recently, reduced interest and concern in the neurological community for the toxicity associated with Mitoxantrone, especially with the arrival and approval of other agents such as natalizumab. In November 2008 a meeting of MS specialists and transplanters was held in Minneapolis under the auspices of NIAID, EBMT and CIBMTR in order to establish shared criteria for the assessment of effi cacy of HSCT in MS and evaluate the feasibility of a new prospective, multicentre trial. The further discussion of options for a multicentre study was the main aim of this panel.
Consensus on the concept of a prospective trial with HSCT in MS
The panel outlined the need for a new prospective trial with a clinical endpoint to be designed within the new scenarios of MS treatment. In particular, the availability of 3-4 new molecules approved for the treatment of the early RR patients is foreseen in the next 1-2 years, resulting in a more complex task. Still we felt there is a continued role for AHSCT in the context of a subset of patients that have demonstrated unusually aggressive early disease activity that is resistant to routine disease modifying agents. The goals of the Florence meeting were to reach a consensus on the following items:
1. Patient selection 2. Defi nition of expected outcomes 3. Transplant technology 4. Study protocol and alternative arm.
S8
S9 1) Patient Selection: The ideal target patients are otherwise young and healthy individuals whose neurological course is characterized by: a) Early phase RR patients within 2-5 years from diagnosis. b) Showing high infl ammatory activity, defi ned as: i) High number (at least 1-2/year) of early disabling relapses. ii) Poor response to steroids (i.e. delayed to poor recovery). iii) Residual accumulating defi cits. iv) MRI showing new T2 or Gd+ lesions. c) All above despite a reasonable trial of effective DMD for 1-2 years. d) Comments: i) Most of MS specialists agree about an expected number of 8-10 patients/year in their respective institutions (~5% of patients) that would meet these criteria. ii) A major issue is to establish criteria for the defi nition of a "reasonable trial of current DMD". In particular, how many DMD failures are needed before moving to HSCT? A consensus was reached that a minimum of a 1 year trial of effective and approved DMD, excluding failures due to intolerance, would be appropriate.
2) Defi nition of expected outcomes: to warrant HSCT, what should be the minimum expectation? a) Most of panel members agree that a 5 year Progression Free Survival, free of immunosuppressive treatment, should be the minimum result of the treatment. b) Both Neurological exams (EDSS, QoL) and MRI are needed for an adequate assessment of effi cacy in the short term. c) Long term follow-up is required to understand the durability of the treatment and to gather continued safety data. d) Improvement in disability at 1 year could be explored as a primary endpoint, in contrast to the usual "not as bad as expected" paradigm.
3) Transplant technology: Most agree that an intermediate to high intensity conditioning regimen be used a) Mobilization regimen: Cyclophosphamide (Cy) and G-CSF is preferred i) Comments:
(1) Most patients improve after mobilization that includes a standard (2-4 g/m 2 ) Cy regimen. (2) Cy reduces the risk of MS potential exacerbation, and also the risk in response to C-CSF. (3) Inclusion of Cy in the mobilization regimen decreases the number of T-cells in the apheresis collection, thereby obviating the need for graft manipulation such as CD34 selection. b) Graft manipulation: probably unnecessary. i) Comments:
(1) Defi nitive clinical data is lacking to show any benefi t of graft manipulation (i.e. CD34 selection). (2) Feasibility of the study would be improved and transplant costs would be reduced if an unselected graft is used (or if a CD34+ selected graft is optional per preference of the site). (3) At least one report indicates an increased risk of infection when patients received anti T-lymphocytes monoconal/polyclonal antibodies in addition to a CD34+ selection. c) Conditioning regimen: BEAM + peri-transplant ATG is preferred by most of the transplanters as an intermediate intensity regimen. However, because some patients showed renewed disease activity in many trials that utilized this regimen, others prefer more complete immunoablative regimens. i) Comments:
(1) Low intensity regimens (i.e. Cy+ATG) are not likely to achieve the goal of 5 years disease, and treatment-free, survival. (2) High intensity regimens (i.e. Busulphan + Cy) can also be considered; it is thought that toxicity might be higher, but with the advent of iv formulations of busulphan and monitoring of blood levels, this might be minimized. (3) BEAM+ATG is the most commonly used regimen in Europe and it showed a satisfactory toxicity profi le in the North-American trial. The issue of components of the BEAM regimen that might be unnecessary for MS such as VP-16 and ARA-C was raised; it was agreed that the concern was reasonable but at the current stage, only regimens widely reported in the literature should be considered.
4) Study protocol and alternative arm -a "delayed randomized crossover treatment" paradigm: a) Inclusion criteria: Active early aggressive patients with RR form failing DMD as defi ned above b) Exclusion criteria: i) Medical contraindications to HSCT. ii) Previous treatment with Alemtuzumab, given the extended period of lymphopenia that results from treatment with this drug, which raises concern on safety of high-dose immunotherapy as well as on a confounding effect on treatment outcomes. Previous treatment with Natalizumab or Fingolimod is accepted following a wash-out period of at least 3 months. c) Randomization of HSCT vs. the best approved medical treatment. d) Failure of treatment leads to crossover (i.e. subjects randomized to the best available treatment and showing evidence of continued disease activity will get eventually get HSCT; subjects randomized to HSCT who demonstrate failure of the primary endpoint will subsequently receive standard care). e) Primary outcome: time to failure. Failure will be defi ned as a combined event made up of incidence of a relapse, MRI activity or EDSS progression. f) Exploration of a one year "improvement" outcome is reasonable, as this will be a randomized study with comparison of two arms, and may signifi cantly reduce the number of subjects needed to be recruited while maintaining a high power.
The panellists agree that further assessment of feasibility and study design should follow in the near future with statistical modelling and outcome refi nement, in particular the concept of how many lines of treatment failures are needed should be defi ned more precisely. Collaboration of both neurologists and transplant physicians will be important to ensure feasibility. Options for randomization schemes and potential funding mechanisms should be developed, to accommodate the multiple participating centres in several countries.
In conclusion, the panel were enthusiastic that there is still an important role for AHSCT in the management of MS today and in the near future. As several well-designed but small uncontrolled studies have been performed to date, it is now timely that a prospective randomized study be developed to further investigate the role of AHSCT in the treatment of MS.
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These data show clinically relevant improvement of skin thickening (defi ned as >25% change in modifi ed Rodnan skin score) in the majority of patients, stabilization of organ function (heart, lung, kidney), signifi cant improvement of functional ability, but at the expense of toxicity and TRM (6%, 95% CI 2%-10% according to the most recent EBMT Registry analysis) with age and PAH as risk factors. 3 Patient eligibility has been broadly similar in different studies, i.e. targeting early dcSSc with some degree of internal organ involvement (mainly lung). Different transplant regimens have been employed, but most included high doses of cyclophosphamide for mobilization and conditioning. No published data are available for lcSSc patients. Comparison with 'historical controls' including those from recent randomized trials cyclophosphamide-placebo, suggest HSCT may induce more robust and sustained responses of skin involvement and functional status, but the benefi ts need to be outweighed against the risks. Two prospective, randomized, controlled trials are in progress, the ASTIS-trial in Europe and the SCOT-trial in North America, to compare safety and effi cacy of HSCT versus iv pulse cyclophosphamide. ASTIS and SCOT trials use similar eligibility criteria and comparable outcome measures and include control treatment with 12 monthly iv pulses cyclophosphamide, but differ in transplant regimen, allowing future comparison of optimal transplant regimen. Accrual in the ASTIS trial has closed, 156 patients were randomized. The SCOT trial is still accruing. Long-term follow-up of patients in these trials is essential to examine possible divergence of survival and study late effects. Only anecdotal data on alloSCT in adult SSc and autoSCT in pediatric cases are available, precluding any conclusions or recommendations.
Based on the available data the following recommendations were made: 1. HSCT in SSc is a complex intervention in a high-risk disease population requiring specifi c expertise of multidisciplinary teams in (EBMT-JACIE accredited) transplant centres. 2. HSCT in SSc should whenever possible be done in the context of a multicentre, clinical trial with well-defi ned endpoints, eligibility criteria, etc and adequate funding for pharmaco vigilance, monitoring, insurance. Provisions need to be made for long-term monitoring of patients. Data reporting to the EBMT central registry (www.ebmt.org) of both the transplant procedure (EBMT MED A Form) and patient's disease characteristics and evolution (EBMT MED B forms) are part of the good clinical practices and the EBMT accreditation process. 3. Cost-effectiveness analyses and mechanistic studies need to be incorporated in future trials whenever feasible. 4. Current uncontrolled data suggest that HSCT can be considered as treatment for selected patients with early dcSSc, but this assessment may be revised once more robust comparative trial data are available. 5. Future studies should address the importance of CD34-selection of the graft and/or in vivo T cell depletion if HSCT proves to be superior in terms of risk/benefi t to conventional iv pulse cyclophosphamide. 6. Comprehensive pre-transplant cardiopulmonary screening of dcSSc patients is critically important. Systemic Lupus Erythematosus (SLE), defi ned according to the ACR criteria, is a heterogeneous chronic autoimmune infl ammatory disorder with a prevalence of 40 to 50/100,000 people. Most of the patients are female (>85%) with a higher frequency in certain ethnic groups, especially amongst black people. The outcome of active severe SLE due to kidney, lung, heart or brain involvement, has improved in the past two decades due to early diagnosis and treatment with immunosuppressive agents combined with overall tighter control of general aspects such as blood pressure and infections. In this context, the fi rst line therapies commonly used at aiming to induce remission within the fi rst 6 to 9 months of disease fl are, are the corticosteroids in combination with cyclophosphamide (CY), which benefi ts over steroids alone were fi rst demonstrated using the classical NIH regimen, but b) currently used at lower doses for shorter duration over 3 months with same effi cacy according to the Eurolupus regimen.
Amongst the other drugs tested for induction or maintenance therapies: a) the use of mycophenolate mofetil (MMF), with early promising results and good tolerability failed to confi rm its superiority to induce remission of lupus nephritis, when compared to standard CY iv in the ALMS trial and also to maintain remission when compared to azathioprine; b) the use of various monoclonal antibodies directed against the T or the B cell receptors or the adhesion molecules involved in the T-B cell interaction and their co-stimulatory signals, such anti CD20 and others agents against IFN, α CD40 all failed to demonstrate their superiority when tested in phase III trials except for the use of belimumab, a monoclonal antibody against BLYS soluble receptor, which was recently shown to be superior to placebo in 2 pivotal phase III trials as induction therapy in SLE patients, leading to new therapeutic indications in this setting.
Despite this progress there are still subgroups of patients who do badly, so much so that even in tertiary referral centres, the 10 year mortality in SLE is 10% with signifi cant morbidity. Although the response range rates vary from 20 to 100% at 6 months according to the defi nition of response or improvement, the extent of visceral involvement, the ethnic origin and the socio economic profi le, among patients with active SLE, overall approximately 20% (10 to 36%) fail to respond, 50% (10 to 65%) will relapse after initial treatment, 5 to 15% will evolve towards end stage disease and 10% to 15% will die at 10 years. Most of these patients have initial renal, cerebral or severe pulmonary involvement, which still appears as an important determinant of a poor long term survival. In addition, prolonged exposure to corticosteroids and immunosuppressive drugs leads to further damage beyond the SLE itself and patient preferences have to be taken in consideration in light of their respective risk factors for potential relapse and long term possibilities of therapeutic observance. With the aim of suppressing autoimmune disease in one concentrated effort rather than drawn out over a long period, an international effort has been studying the feasibility and the efficacy of autologous Hematopoietic Stem Cell Transplantation (HSCT) since 1994. Jayne et al. reported the EBMT experience in 2004 with 53 SLE patients, mostly female (83%) after a mean of 6 years disease duration, treated by Autologous Hematopoietic Stem Cell Transplantation (ASCT) with a mean follow-up of 26 mths after HSCT in 23 centres. Cyclophosphamide and ATG were the most often used conditioning regimen. Remission of disease activity (SLEDAI <3) was seen in 33/50 evaluable patients by 6 months, of which 10/31 subsequently relapsed after 6 months. Renal and central nervous system lupus activity also improved with a concomitant decrease in antidsDNA titres and increase in complement. Impressively, it was possible to fully withdraw prednisolone therapy in 36% of patients. TRM appeared high (12%) at that time and the return of disease activity in one-third of patients might be reduced by long-term immunosuppressive therapy post-AHSCT. Since then, the Chicago group reported single centre experience of 50 SLE patients refractory to standard immunosuppressive therapies and either organ-or life-threatening visceral involvement, showing a durable remission with low transplant related mortality (TRM) of 2% (1/50) and by intention to treat analysis of 4% (2/50). PBSC were mobilized with CY (2 g/m 2 ) and GCSF (5 μg/kg/day) enriched ex vivo by CD34+ immunoselection, cryopreserved and reinfused after CY (200 mg/kg) and equine ATG (90 mg/kg). Two patients died after mobilization, one from disseminated mucormycosis and the second from active lupus after postponing transplantation for 4 months. With a mean follow-up of 20 months, the overall survival was 84% and the PFS at 5 years was 50%. Secondary analysis showed stabilization of renal function and signifi cant improvement in SLEDAI score, ANA, anti DNA, complement levels and Diffusion Lung Capacity adjusted for haemoglobin. In 2009, analysis of the 900 Autoimmune Diseases patients from the EBMT database among (64% female, median 35 years) with fi rst autologous HSCT showed that 3 years after HSCT amongst the 85 lupus erythematosus, the PFS was 54% (95% CI: 42%-66%) and the overall survival probability was 87% (95% CI: 79%-95%). In addition, interesting results showing the possibility of resetting the autoimmune response and inducing tolerance with expansion of T regulators cells and of de novo naïve T cells after HSCT, after autologous HSCT, shed new light in the use of this new therapeutic approach not only in SSc, MS, JIA, but also in Lupus patients. Based on these results, a prospective open, multicenter, phase II study using AHSCT as a remission induction, followed by MMF (up to 2 g/day) as maintenance therapy started 3 months after inclusion in patients with severe SLE is necessary. It will evaluate, as the primary objective, the safety (TRM and toxicity up to 2 years after inclusion) and also effi cacy of AHSCT as induction therapy followed by maintenance therapy by Mycophenolate Mofetil in the treatment of severe SLE refractory to standard therapy. Secondary objectives will evaluate: 1) the long term effi cacy according to repeated measures of Disease Activity and Damage scores, Quality of Life, the presence of other co-morbidities, the daily dose of steroids rated quarterly up to two years after AHSCT; and 2) whether remission and disease activity correlates with immunological parameters, including immune reconstitution and auto antibodies.
Inclusion criteria are: 1) age between 16 and 60 years; 2) systemic SLE according to ACR-criteria with ANA on at least 2 successive tests at 3 months interval plus disease duration ≤ 5 years; S12
3) since the diagnosis or the onset of any of the following sustained or relapsed active renal BILAG A SLE with documented evidence of at least one visceral involvement or refractory SLE as defi ned by either: 3.1 kidney involvement: with the criteria for lupus renal BILAG A and a creatinine clearance>30 ml/min/m 2 , not explained by other causes than SLE activity with a renal biopsy of less than 12 months showing a class III, IV or V lupus nephritis; 3.2 any other type of vital organ involvement except mesenteric vasculitis with BILAG neurologic category A, cardiovascular or pulmonary category A, vasculitis category A; 3.3 auto-immune cytopenias (hemolytic anaemia and/or thrombo-cytopenia) defi ned as BILAG hematologic category A and confi rmed by a bone marrow aspirate; 3.4 Secondary antiphospholipid syndrome (SAPL) active despite full (INR>3) anticoagulation; 4) after at least 6 months of the best standard local therapy using CY or MMF or anti CD20 (Rituximab) either alone or successively according to: a) the short term Eurolupus protocol low dose CY regimen of 6 × 500 mg iv CY at 2 weeks interval or b) the conventional treatment with 0.75 g/m 2 /month × 6 iv cyclophosphamide and c) MMF at least 2 g daily for 3 to 6 months plus oral steroids above 0.5 mg/kg/day and be corticosteroids dependent and unable to decrease below 20 mg/day. 5) Ability to understand and to provide signed written informed consent.
Treatment: 1) mobilization with CY 4 g/m 2 (in two divided doses), followed by 2) Autologous Hematopoietic Stem Cell Transplantation using CY (200 mg/kg body wt in 4 daily doses) plus rabbit ATG and unmanipulated autologous graft 3) and maintenance by Mycophenolate Mofetil (2 g/day) started 3 months after AHSCT and maintained up to 24 months.
The primary effi cacy endpoints will be the proportion of patients alive who achieve clinical success at 12 months and maintenance of this status until 24 months after inclusion and secondary effi cacy endpoints will be: 1) Treatment completion; 2) Clinical success at 3, 4 and 5 years;
3) The mean steroids daily dose will be recorded during the 12th months and the 24 months; 4) Disease activity assessed by the BILAG (from 0 to 72) and the SLEDAI (from 0 to 105) index scores; 5) Disease damage assessed by the SLICC/ACRR Damage Index; 6) Quality of Life; 7) The number of treatment failure. Safety endpoints will be: 1) Treatment related mortality; 2) All causes of mortality 3) Treatment related toxicity 4) Engraftment.
The estimated total sample size required is 30 patients. Stopping rules for effi cacy and ineffi cacy of the procedure will be applied. If the stopping rules recommend the end of the trial, an independent expert committee will decide about stopping or continuing of the trial. The duration of the study is 5 years with open enrolment for 3 years and study follow up of 2 years. Every patient will be assessed on a quarterly basis throughout the 2 years of the study after transplant with a 3 years post study follow-up.
INTRODUCTION
Crohn's disease (CD) is an infl ammatory bowel disease (IBD) [1] that represents an emerging threat due to a recent increase in its frequency. CD is characterized by chronic clinical course, with alternation of exacerbations and remission, and by a trans-mural infl ammation that could affect any portion of the digestive tract. In the last years, a lot of effort has been made to identify the mechanism underlying the onset of CD. The discovery of the NOD2/CARD15 gene [2] and studies conducted on monozygotic twins, that showed a concordance above 50% [3] , have pointed out a genetic susceptibility to develop CD. These fi ndings, supported by clinical and experimental studies that demonstrate a breakdown of intestinal immune homeostasis, have given rise to the idea that in the presence of a genetic predisposition, the exposure to unknown antigens could trigger an immune response, leading to the onset of the disease. Nevertheless, the true pathogenesis of CD still remains unclear. Current treatments are based on antibiotics to reduce bacterial bioburden, immunosuppressive therapies and, recently, biologics such as anti-TNF for immune modulation. Despite a good response in the majority of patients, there is still a subgroup of patients with an unsatisfactory course, who develop progressive tissue damages, requiring surgery. This evidence has pointed out the needed for a new treatment approach. Hematopoietic stem cells transplantation (HSCT) has emerged in the last years as a promising therapeutic strategy for patients with aggressive autoimmune diseases who are refractory or intolerant to conventional treatments. Considering the genetic susceptibility associated with NOD2/CARD15 mutation and basing on experiences from animal models [4, 5] , allogeneic HSCT seems to have greater capability to induce a long-term remission than autologous transplantation. Nevertheless, because of the higher toxicity of allogenic HSCT and the evidence of effi cacy from case reports treated with autologous HSCT (AHSCT), initial clinical research has focused on this latter approach in treating CD patients. Further support to the role of autologous HSCT arises from the encouraging experiences matured with other AD and from the data on the immunological recovery after transplantation [6] . These fi ndings suggest that high dose chemotherapy followed by autologous HSCT could have the capacity to eradicate autoreactive T-effector/memory cells, therefore restoring immunological tolerance by resetting the immune system to an early phase [7] .
EVIDENCE OF THE EFFECTIVENESS OF HSCT IN CROHN'S DISEASE
The fi rst clinical evidence of effectiveness of transplantation was reported with the observation that patients with CD, who underwent allogenic or autologous HSCT for a haematological or solid malignancy, experienced long-lasting remission of their IBD. Out of the twenty-two cases treated with allogeneic HSCT and reported so far [8] , 19 experienced a durable complete remission of the CD, while two patients died from infectious complications and one experienced an early clinical relapse. Although few cases regarding autologous HSCT in concomitant CD and malignant diseases have been reported, collected data have shown similar results to allogeneic transplantation in terms of remission [9, 10] . Beyond case reports [11] , autologous HSCT as primary treatment for CD has been investigated in two single-centre phase II studies [12, 13] . Despite the low number of patients and their limited follow-up, autologous HSCT was shown to have the capacity to induce complete clinical and endoscopic remission, with impressive results.
PROSPECTIVE TRIAL, ASTIC (http://www.nottingham. ac.uk/icr/astic/) ASTIC is a multicentre, prospective, randomised phase III study conducted by the European Crohn's and Colitis Organisation (ECCO) and sponsored by the European Group for Blood and Marrow Transplantation (EBMT). The aim of the trial is to evaluate the safety and the tolerability of HSCT and the impact of this therapeutic approach upon the clinical course of CD. Following mobilization (with cyclophosphamide 4 g/m 2 and G-CSF) and collection of stem cells, patients are randomized to an early (within four weeks) or to a late (after 12 months) autologous HSCT, in order to compare the effect of the conditioning regimen (including intravenous cyclophosphamide 50 mg/kg/day for 4 consecutive days and intravenous rabbit antithymocyte globulin (rATG) 2.5 mg/kg/day for 3 days) followed by AHSCT to the single stem cells mobilization's effect followed by best available treatments in CD. This study is actually the only ongoing prospective trial in this fi eld and is therefore an indispensable instrument to assess the role of AHSCT in CD.
PANEL WORKSHOP
HSCT in Crohn's disease has only recently been investigated and a lot of unanswered questions remain. The panel discussion was focused on the impressive results which were obtained from single centres' experiences. Nevertheless the need for a larger cohort study was considered indispensable for the future. ) in association to G-CSF is the most widely used scheme in autoimmune diseases. Nevertheless is not yet clear whether this association is necessary also in CD. Future analysis should investigate this point in order to assess if it is possible to reduce mobilization-related toxicity, taking into consideration that the use of G-CSF alone for mobilization has been linked to disease fl are in various autoimmune conditions. c. Conditioning: currently, a widely adopted regimen in CD includes cyclophosphamide 200 mg/kg and antithymocyte globulin (rATG, total dose 7.5 mg/kg). This conditioning regimen has proven to be safe and effective in phase II single centre trials [12, 13] . Nevertheless considering the lack of a clear understanding in CD's pathogenesis, future directions taking into account also indications from basic science, should be explored with prospective trials. d. Because some relapses of CD have been reported following AHSCT, future studies should investigate if a maintenance treatment after autologous HSCT might be effective in preventing disease recurrence. 4. Prospective trial and future directions: autologous HSCT must be still considered an experimental treatment. For that reason, patients should be encouraged by their physicians to receive this treatment within prospective trial (such as ASTIC). Autoimmune cytopenias are relatively frequent and do often respond to treatment. Non-responding patients have a chronic disease which may vary from mild to very severe. The autoimmune cytopenias that may be considered for haematopoietic stem cell transplantation are immune thrombocytopenia (ITP), autoimmune hemolytic anemia (AIHA) and Evans syndrome. Other diseases include autoimmune neutropenia and other rarer entities. The WPAID holds data on a few cases with ALPS (autoimmune lymphoproliferative syndrome) which are felt to belong to the immunodefi ciency diseases, cases of cryoglobulinemia which should be considered among the vasculitides and thrombotic thrombopeneic purpura. Aplastic anemia, pure red cell aplasia (PRCA), amegakaryocytic thrombocytopenia are formally also autoimmune cytopenias but T-cell mediated rather than with autoantibodies and these entities are traditionally registered within working party aplastic anemia of the EBMT. The available data were discussed; there are 52 patients with ITP, AIHA, Evans syndrome who have received autologous or allogeneic HSCT between 1996 and 2008 by 50 centers. Results of some of these patients have been reported in a previous paper in the BJH in 2004. Overall survival at 5 years is 61 ± 5%. There are, in addition, data on 84 patients (median age 14 yrs) with PRCA in the WPSAA database, almost exclusively receiving allogeneic HSCT (overall survival at 5 years 68 ± 11%). Transplant procedures for the 52 patients were very heterogeneous with many different conditioning regimens used.
After discussion of the current results, the proposal was to:
1. Coordinate an analysis of available data with CIBMTR; 2. Propose a common strategy for patients with ITP, AIHA and Evans syndrome in order to harmonize treatment so that meaningful analysis can be done in the future (to answer questions like "Which patients are most likely to benefi t for HSCT?" or "Is cytopenia-free survival higher after autologous or allogeneic transplant?"). It was proposed a. to include patients with ITP, AIHA and Evans syndrome refractory to 2 -3 lines of treatment; b. to initiate a donor search and to perform an allogeneic transplant in young patients (< 50 years) if a sibling donor is available and to proceed to an alternative donor search only if the patient is of pediatric age. In the case that no donor can be identifi ed, autologous HSCT is preferred; c. to recommend conditioning is with fl udarabine, cyclophosphamide and ATG for autologous as well as allogeneic HSCT; d. to recommend no ex vivo T-cell depletion, and as graft type, peripheral blood for autologous and marrow or cord blood for allogeneic transplantation. This is not a formal study protocol but rather a treatment outline with the recommendation to then report all patients to EBMT or CIBMTR. Given the low number of transplants per center (median number =1 over 10 years), it is highly unlikely that a prospective study can ever be done at the same time there are some patients who have clearly benefi tted from the procedure. Harmonizing the procedures may yield more interpretable data in the future.
FINAL REMARKS FROM THE PANEL DISCUSSION RESULTS

Alberto Marmont
Department of Haematology, Ospedale di San Martino, Genoa, Italy These fi nal remarks are proposed before the session's presentation, which cover the results of HSCT for its main indications in the galaxy of severe autoimmune diseases (SADs), namely MS (a theme thoroughly discussed in a recent Meeting in Moscow), SSc, SLE, CD and hematocytopenias. In a recent Perspective I have posed four main questions concerning the autologous procedure, including the most appropriate mobilizing and conditioning regimens, the procedure's safety, its mechanism of action and its comparison with the best available non-transplant based treatments. The prospective randomized trials should by now shed some light most especially on this last point. The allogeneic procedure carries by defi nition a greater promise, there are already some multicentric evaluations, but there are still some controversial results. At the end of the prospective trials it may be predicted that there will be a fruitful integration of different therapeutic lines for the single patient. 
S15 LUNCH SYMPOSIUM: HSCT FOR ADS: CLINICAL TRIALS DESIGN STATISTICAL CONSIDERATIONS FOR CLINICAL TRIALS IN AUTOIMMUNE DISEASES
Myriam Labopin
Hospital Saint-Antoine, Paris, France
The major challenge in clinical research when trying to access the relationship between a treatment and the outcome of a disease remains to avoid Bias. A bias is a systematic error in the estimation of the measure of association between the factor studied and the outcome. This confounding factor is linked both to the factor studied and to the outcome. In evidence based medicine (EBM), Randomized Clinical Trials (RCTs) are considered as the best method for revealing the effects of a therapeutic intervention because non-randomized controlled trials are more likely to suffer from bias than RCTs. However, RCT maybe not feasible due to ethic consideration or practical reasons such as exclusion criteria, long term follow-up, patient and physician decisions. All these situations are encountered in the fi eld of ADs. The evaluation of hematopoietic stem cell transplantation (HSCT) in patients suffering from ADs raises different issues. If in one hand phase II studies can be easily designed and performed, in the other hand the real benefi ce of the procedure is diffi cult to evaluate. When planning to design a RCT, ethical problems are related to randomization between one arm leading to 1 to 5% mortality (HSCT) versus one arm with a good safety profi le. Other important issues are the choice of the patients that will be candidate for HSCT, the assessment of the outcome through an activity score, the notion of drug-free remission and the long term follow-up needed for assessing a real benefi t.
In the absence of randomized trials, observational studies can be run including case series, case control and prospective cohort studies.
In all these studies, a major concern is the choice of the study endpoints chosen to assess treatment effects related to effi cacy and safety. The standardization of the defi nitions of endpoints is necessary to ensure comparability between trials.
SURROGATE MARKERS IN MS CLINICAL TRIALS
Maria Pia Sormani
University of Genoa, Genoa, Italy
The primary effi cacy outcome in confi rmatory clinical trials should be the variable refl ecting the most important aspect in terms of quality and/or duration of life of patients. In particular, in multiple sclerosis (MS) the primary outcome should be a clinically measured prevention or delay of disability progression and the incidence of clinical relapses. For practical reasons, clinical trials in MS usually do not last longer than 2 to 3 years, although the accumulation of irreversible disability usually occurs over a longer time period. Moreover, very large samples of patients need to be recruited for such trials, in order to obtain an adequate statistical power to evaluate progression of disability. In addition, with new therapies available, having placebo arms in phase III poses many unsolved ethical problems. Sample sizes may be even larger if superiority over an active comparator or non-inferiority designs are pursued. As a consequence, the use of surrogate outcome measures would be an attractive, if not an inestimable, strategy to overcome the present situation in designing, planning and conducting clinical trials in MS. Moreover, demonstrating the validity of a surrogate marker in MS might prove to be important for daily-life decisions regarding individual patients' treatment.
As a non-invasive and increasingly available approach, magnetic resonance imaging (MRI) offers several advantages over the accepted clinical outcome measures for MS, including an increased sensitivity to disease activity, and a better association with histopathology fi ndings than that with clinical manifestations. MRI also provides highly reproducible measures on ordinal scales, thus allowing a more powerful statistical approach. In addition, the assessment of the MRI scans can be performed at the highest degree of blinding and MRI data are retrievable for new, not pre-planned analyses [modifi ed from: Bar-Zohar et al., Mult Scler 2008 (1)]. The "trial level surrogacy" was tested in MS in a large metaanalysis of all the published trials in RRMS reporting data both on MRI variables and relapses (2). The results of this meta analysis (23 trials, 6591 patients) indicated a strong correlation between the effect of therapy on active lesions and the effect of therapy on relapses. This correlation accounted for more than 80% of the variance in the relationship (Figure 1 ).
This observation could have important implications for the general strategy of clinical trials in RRMS.
At present, standard practice is to conduct short term phase II studies based on MRI lesions to determine if a defi nitive trial with a clinical endpoint as the primary outcome should be contemplated. However, this practice is based more on empirical reasoning than on evidence; the results of the meta-analysis provide solid scientifi c evidence for current trial practice and supports the use of MRI parameters as endpoints in phase II trials. In fact, based on the meta analysis results, once a drug has been shown to be active on MRI lesions in a phase II setting, the prior probability of an effect on relapses is strongly increased and this effect can be indirectly estimated. This information can be used both in the decision to run a phase III trial, and in its design. This gives also support for the use of MRI markers as primary endpoints in trials evaluating analogues or different ways of administration of drugs of proven effi cacy, if the available data from previous trials confi rms a relationship between their effects on MRI markers and on relapses, according to the estimated regression equation. Type 1 diabetes mellitus (T1DM) results from an autoimmune aggression to insulin producing beta-cells in the pancreas mediated mainly by autoreactive T cells (CD4+ and CD8+). Acute or chronic immunosuppression in recently diagnosed patients produces clinical benefi t and allogeneic bone marrow transplantation prevents disease development in susceptible strains of mice. Based on that evidence and on the success of autologous hematopoietic stem cell transplantation in other forms of autoimmune diseases, our group started in December/2003 a phase I/II trial of autologous HSCT in 12-35 y old patients with <6 weeks from diagnosis. Three patients with either previous ketoacidosis or using steroids in the conditioning did not respond to therapy. However, the vast majority of patients (n=20) without those features became insulin-free transiently or continuously in different times along mean follow-up of 39.8 months. In most patients, time of insulin suspension was day -3 to +6 relative stem cell infusion. In the 11 patients transiently insulin-free mean time of insulin independence was 20.4 months (ranging from 6 to 47 months). Of these, 2 patients (#2 and #4) became transiently insulin-free for 47 and 43 months, respectively. After 4 and 2 months of resuming insulin and using daily insulin doses of 0.25 and 0.20 IU/kg, respectively, we opted to add sitagliptin (a dipeptidyl peptidase 4 inhibitor) 100 mg/d orally. Both became completely insulin-free again after 2 months for 2 and 1 months using sitagliptin and both remained free from exogenous insulin for 16 and 17 months, respectively. In face of this fact, we included sitagliptin to all relapsed patients. The majority of relapsed patients use small amounts of basal insulin once a day with good glycemic control. Of the 9 patients continuously insulin-free, the mean period of insulin-independence is 44.6 months, ranging from 27 to 63 months. Interestingly, mean area under the curve of C-peptide levels during mixed meal tolerance test (a marker of β cell function) increased signifi cantly in both groups, regardless the need of exogenous insulin use. In 2009, we opted to include patients with a longer time of diagnosis of T1DM (<3 months). To date, only 1 patient with 3 months was included and he got complete insulin suspension 3 days after stem cell infusion and he is 2 months free from exogenous insulin. Important adverse effects were bilateral pneumonia in 2 patients, late endocrine dysfunction in 3 patients (Graves disease, hypothyroidism and transient hypergonadotrophyc hypogonadism), and oligospermia in 9 patients. There was no mortality.
STEM CELL TRANSPLANTATION IN AUTOIMMUNE DISEASE
Alan Tyndall, on behalf of EULAR University Department of Rheumatology, Basel, Switzerland
During 1995 informal discussions between members of the scientifi c committee of the European League Against Rheumatism (EULAR) and the European Group for Blood and Marrow Transplantation (EBMT) concerning the potential of haematopoietic stem cell transplantation (HSCT) for the treatment of severe autoimmune diseases (AD) resulted in a consensus statement and the commencement of small phase I/II trials (1, 2). The mission statement of the working group was, and remains "to show through prospective, randomised controlled trials (RCT) the place, if any, of HSCT in the treatment of severe AD." A secondary aim is to increase the understanding of AD onset and persistence through mechanistic scientifi c side-studies. With time, important partners joined the group such as neurology and gastroenterology and a dynamic interface and collaboration with North American partners was developed. The SCOT trial is accruing patients and has been described in another session of this meeting. As of June 2009, 156 subjects have been enrolled and screened to confi rm protocol eligibility. Before randomization, all patients require authorization by their health insurance carrier to pay for these previously published treatments. Patients with poor prognosis systemic sclerosis are enrolled, the majority with severe pulmonary involvement. Mean entry characteristics of 57 randomized subjects include: age, 46 years; Rodnan skin score, 32; Forced Vital Capacity (FVC), 76% predicted; and Carbon Monoxide Diffusing Capacity (DLCO), 53% predicted. The leading (and related) causes of enrolled patients not proceeding to randomization and treatment were: denial or delay by health insurer to fund therapy, and progression of pulmonary impairment to levels below entry criteria. Of the fi rst 96 enrolled subjects requesting health insurance payment, 51 (54%) were denied funding. Patients next submitted appeals through their insurers for outside review. First and second appeals required 2 -7 months to complete resulting in 64/95 (67%) of individuals ultimately being approved for the trial. Treatment funding decisions by insurers varied greatly both within the same health plan and across different plans. Of those funded for treatment and randomized, subjects gave consent for mechanistic studies and collection of repository specimens. To date, over 4,000 samples have been stored at baseline and 10 time points up to year 5 after randomization. Stored materials include: serum, plasma, cells, DNA and RNA. Recently, requests for proposals for scientifi c study using repository specimens were sent to North American rheumatologists and to medical center basic science departments. Requests from European investigators will also be considered. In addition to this biobank, the National Institutes of Health (NIH) has funded several ongoing mechanistic investigations: T-cell immunity; molecular biology of fi brosis; TGF-beta superfamily biomarkers; microchimerism in dermal tissues; vascular endothelial progenitor analysis; cyclophosphamide pharmacokinetics; microvasculature imaging; computerized analysis of standardized chest and thymic tomographic imaging; and comparability studies of blood stem cell selections across sites. In summary, this study illustrates the challenges of conducting clinical treatment trials in the U.S. health insurance system as well as the vibrant opportunity and NIH support for basic science investigations within a pivotal clinical trial.
NEW THERAPEUTIC STRATEGIES IN SLE
Falk Hiepe
Charité Universitätsmedizin Berlin, Berlin, Germany SLE is a systemic autoimmune disease with heterogeneous clinical manifestations. It is amongst others characterized by the generation of pathogenic autoantibodies and complement activation. The current treatment includes antimalarials, glucocorticoids and immunosuppressive/cytotoxic drugs such as cyclophosphamide, mycophenolate mofetil and azathioprine. These drugs have markedly improved the patients' outcome. However long-term treatment with these drugs, which is often necessary has resulted in a change of morbidity and mortality including increased risk of infections, cardiovascular disease, malignancy etc. Nevertheless, there is a subset of patients who are refractory to these therapeutic regimens. Recently, biologics targeting B cells (anti-CD20, anti-CD22, anti-BLys, TACIIg), co-stimulatory molecules (CTLA-4-Ig) and cytokines (TNF blockers, blockers of interferon-alpha) have been emerged as therapeutic options in SLE. Especially, B cell depletion therapy (BCDT) with a monoclonal anti-CD20 antibody has been successfully used in refractory patients. Against this experience, a controlled trial with BCDT failed the endpoints, which is probably due to the study design. There is the proof-of-principle that the ablation of the autoreactive immunological memory followed by autologous stem cell transplantation can result in long-term remission without continuation of immunosuppression due to a reset of a tolerant immune system. Therefore, candidate targets for potential curative approaches are long-lived plasma cells as part the autoreactive immunological memory. They survive in niches in bone marrow and infl amed tissues despite immunosuppression and secrete pathogenic antibodies.
HIGH-DOSE IV CYCLOPHOSPHAMIDE AND COPAXONE IN AGGRESSIVE RELAPSING REMITTING MULTIPLE SCLEROSIS
Douglas Kerr MD/PHD, Adam Kaplin MD/PHD, Edward Hammond MD, Richard Jones, MD, Robert Brodsky MD Johns Hopkins University School of Medicine, Baltimore, USA Multiple sclerosis (MS) is an autoimmune disease characterized by progressive immune-mediated destruction of myelin and axons within the CNS. High-dose cyclophosphamide (HiCy) is one-time chemotherapy treatment option for severe, refractory, immune-mediated illnesses such as MS. There is growing evidence that HiCy is well tolerated and effective in MS. Our experience with 9 patients who underwent treatment at the Johns Hopkins Hospital yielded impressive results with a signifi cant 39% reduction in baseline disability and an 81% reduction in MRI gadolinium enhancing lesions. Four out of 9 patients did not have evidence of clinical or imaging recurrence during 24 months of follow-up, wheras fi ve out of nine patients exhibited radiologic or clinical reactivation, usually in the fi rst year after HiCy. Our fi ndings suggest that high-dose cyclophosphamide holds promise in inducing remission and reducing disability in RRMS. However the recurrence of MS disease activity suggests that high-dose cyclophosphamide given as a treatment on its own, is not suffi cient to induce long-term remission in some patients. Glatiramer acetate (GA) has been shown to be a more general suppressor of autoimmune disease, inhibiting the onset of experimental animal models of uveoretinitis, rheumatoid arthritis, immune rejection of grafts against host and host against graft disease, and infl ammatory bowel disease. A unique feature of GA is its promiscuous binding with high affi nity to various class II MHC molecules and its potent induction of Th2 regulatory T cells. GA is approved by the FDA for treatment of MS. We plan to investigate the properties of GA against the recurrence of MS disease activity following high dose cyclophosphamide induced cessation detectable autoimmunity. We hypothesize that GA, given in the phase of immune reconstitution after HiCy, may bias the immune system to a more tolerized state, thus leading to more stable and potentially permanent remissions. In a pilot study currently underway, we have treated approximately 40 RRMS patients with HiCy followed by Copaxone and have followed them for up to 24 months. In this cohort as well, there is a greater than 30% reduction in disability as defi ned by EDSS scores (reduction of approximately 2.2 EDSS points). 2/40 patients has exhibited a clinical exacerbation. 3/40 patients has exhibited a new, or gadolinium enhancing brain lesion. 35/40 patients have no evidence of disease reactivation. Though preliminary, this suggests that the combination of HiCy followed by Copaxone may cause a sustained reduction in disability and disease activity that exceeds that of HiCy alone. Objective: Autologous non-myeloablative haemopoietic stem cell transplantation is a method to deliver intense immune suppression. We evaluated the safety and clinical outcome of autologous non-myeloablative haemopoietic stem cell transplantation in patients with relapsing-remitting multiple sclerosis (MS) who had not responded to treatment with interferon beta. Methods: Eligible patients had relapsing-remitting MS, attended Northwestern Memorial Hospital, and despite treatment with interferon beta had had two corticosteroid-treated relapses within the previous 12 months, or one relapse and gadoliniumenhancing lesions seen on MRI and separate from the relapse. Peripheral blood haemopoietic stem cells were mobilised with 2 g per m 2 cyclophosphamide and 10 μg per kg per day fi lgrastim. The conditioning regimen for the haemopoietic stem cells was 200 mg per kg cyclophosphamide and either 20 mg alemtuzumab or 6 mg per kg rabbit antithymocyte globulin. Primary outcomes were progression-free survival and reversal of neurological disability at 3 years post-transplantation. We also sought to investigate the safety and tolerability of autologous non-myeloablative haemopoietic stem cell transplantation. Results: Between January, 2003, and February, 2005, 21 patients were treated. Engraftment of white blood cells and platelets was on median day 9 (range day 8-11) and patients were discharged from hospital on mean day 11 (range day 8-13). One patient had diarrhoea due to Clostridium diffi cile and two patients had dermatomal zoster. Two of the 17 patients receiving alemtuzumab developed late immune thrombocytopenic purpura that remitted with standard therapy. 17 of 21 patients (81%) improved by at least 1 point on the Kurtzke expanded disability status scale (EDSS), and fi ve patients (24%) relapsed but achieved remission after further immunosuppression. After a mean of 37 months (range 24-48 months), all patients were free from progression (no deterioration in EDSS score), and 16 were free of relapses. Signifi cant improvements were noted in neurological disability, as determined by EDSS score (p<0.0001), neurological rating scale score (p=0.0001), paced auditory serial addition test (p=0.014), 25-foot walk (p<0.0001), and quality of life, as measured with the short form-36 (SF-36) questionnaire (p<0.0001). Conclusion: Non-myeloablative autologous haemopoietic stem cell transplantation in patients with relapsing-remitting MS reverses neurological defi cits, but these results need to be confi rmed in a randomised trial.
AUTOLOGOUS NON-MYELOABLATIVE HAEMOPOIETIC STEM CELL TRANSPLANTATION IN RELAPSING-REMITTING MULTIPLE SCLEROSIS
ABSTRACTS ACCEPTED FOR THE ORAL SESSION
AUTOLOGOUS NON-MYELOABLATIVE HAEMATOPOIETIC STEM CELL TRANSPLANTATION FAVOURABLY MODIFIES THE BALANCE OF REGULATORY AND PRO-INFLAMMATORY T CELL SUBSETS S. Abrahamsson
(1) , A. Dubinsky (2) , D. Angelini (3) , U. Oh (4) , L. Battistini (3) , R. Martin (5) , R. Burt (6) , P.A. Muraro (1, 4) (1) Imperial College (London, UK);
(2) University of Iowa (Iowa City, USA); (3) Fondazione Santa Lucia (Rome, IT); (4) National Institutes of Health (Bethesda, USA);
(5) University Medical Center Eppendorf (Hamburg, DE) ; (6) Northwestern University (Chicago, USA)
Objective: Clinical studies have confi rmed prolonged suppression of central nervous system infl ammation (CNS) in the majority of the patients treated with autologous haematopoietic stem cell transplantation (AHSCT) for multiple sclerosis (MS). A recently published clinical trial of non-myeloablative AHSCT showed that the treatment was well tolerated and lead to stabilization and even clinical improvement in patients with relapsing-remitting MS (Burt et al., 2009) . We aimed at identifying immunological mechanisms involved in reinstating tolerance in a subset of the patients treated in this trial. Methods: We studied 12 patients with relapsing-remitting MS who were treated with a conditioning regimen consisting of cyclophosphamide and alemtuzumab before reinfusion of a CD34-selected autologous graft. Blood samples were collected at study visits for a period of 2 years. We assessed peripheral immune reconstitution, evaluating markers for functional differentiation, regulation and cytotoxicity, and defi ning subsets by cytokine production. Results: A preferential expansion of memory T cells contrasted with the mechanics of immune reconstitution previously described for AHSCT with high-dose immune suppression. Qualitative differences of the lymphocyte pool indicated increased contribution of immune regulatory circuits post-therapy. FoxP3+/ CD25hi CD4 cells and CD56high NK cells were increased at 6 months of follow-up. Of interest, a CD8 T cell population characterized by the expression of CD57 and with suggested immunosuppressive capacity, was signifi cantly increased for the entire 2-year follow-up (P<0.001). We further characterized the CD8 cells by the expression of regulatory receptors previously described on NK cells. We found that ILT2 (CD85j), an inhibitory receptor, was much more frequently expressed in CD57+CD8 cells than in the CD57-subset. We speculate that ILT2 increases the activation threshold of CD57+CD8 cells. In contrast, a CD8 subset with high expression of CD161 (NKRP1A) was found in all patients prior to treatment, but was almost undetectable after therapy (P<0.001). CD161 on CD8 T cells defi ned a pro-infl ammatory cell subset that produced IFNg and contained virtually all IL-17 producing CD8 cells. They further expressed CCR6, a marker that was recently demonstrated to be involved in transmigration of cells to the CNS. We suggest that CD161hiCD8 cells represent a new subset with pathogenic potential in MS. Conclusion: Our data show signifi cant qualitative and functional changes in the reconstituted immune response following reduced intensity AHSCT. We demonstrate improved regulatory activity, thought to be important to establish control of potential autoimmunity at the time of new antigenic priming, as well as the elimination of a Tc17 subpopulation with pathogenic potential. We propose that a modifi ed balance of pro-and anti-infl ammatory cells subsets could contribute benefi cially to the outcome of AHSCT.
Bone marrow derived mesenchymal stem cells (BM-MSC) have been characterized as multipotent cells, which are able to differentiate into several mesodermal and non mesodermal lineage cells. This feature along with their extensive expansion potential and immunomodulatory properties establish them as a promising tool in the treatment of immune mediated diseases. Their immunomodulatory effect is dependent on the microenvironment in which the interaction between BM-MSCs and cells of the immune system takes place. We studied the infl uence of murine BM-MSCs both in vitro and in vivo on the activation of B cells in NZB/NZW F1 mice as an animal model of systemic lupus erithematosus (SLE). BM-MSCs inhibited antigen dependent proliferation and differentiation to plasma cells of follicular and marginal zone B cells in vitro. This inhibitory effect was dependent on IFN-γ mediated by cell to cell contact, involving PD-1/ PD-L1 interaction. Although BM-MSCs inhibited B cells antigen dependent proliferation and differentiation in vitro, in vivo treatment with BM-MSCs did not affect anti-ds DNA antibodies level and proteinuria. However a reduction in glomerular immunocomplexes deposition, lymphocytic infi ltration and particularly glomerular proliferation was observed, supporting a potential role of mesenchymal stem cells in the prevention of glomerular damage. Multiple sclerosis (MS) is the most frequent autoimmune disorder of the central nervous system in young people. In about 3% of the patients MS course is aggressive with severe attacks and rapid accumulation of neurological disability despite adequate conventional treatment. In such cases high-dose immunoablation with autologous hematopoietic stem cell transplantation (ASCT) should be considered. Aim of the study: To describe our group of 26 MS patients (pts) who have been treated with ASCT within years 1998-2008. Methods: 26 pts (characteristics at the time of ASCT: F/M= 15/11, age 32±7 years, Expanded Disability Status Scale (EDSS) 6.0±1.5, MS duration 8±4 years), 4 relapsing-remitting (RRMS), 7 relapsing-progressive (RPMS) and 15 secondaryprogressive (SPMS) pts with aggressive MS underwent ASCT after informed consent signing. MS treatment before ASCT involved interferon beta -IFNb (n=21), glatiramer acetate -GA (6), intravenous immunoglobulins -IVIG (11), cyclophosphamide -CPA (19), mitoxantron (16), azathioprine (24). Stem cells were mobilized by high-dose CPA and granulocyte colony-stimulating factor, ex vivo purging of the graft was performed in 13 pts, BEAM regime (BCNU, etoposid, cytarabin, melphalan) was used for immunoablation, anti-thymocyte globulin was administered on day +1 and +2 in 15 pts. Early and late ASCT adverse events (AEs) were evaluated together with EDSS before and every three months after ASCT. Follow-up period was 13-134 months (median 68 months). Progression free survival (PFS) was calculated using Kaplan-Meier method. Results: PFS for the whole group was three years in 70.8% and six years in 29.2% of the pts -Graph 1. A more favourable outcome has been achieved in the subgroup of RRMS and RPMS pts compared to SPMS pts (p=0.00002) -Graph 2, in the pts with disease duration shorter than 5 years (p=0.00217) and age under 35 years (p=0.01118). MS treatment after ASCT involved IFNb (n=2), GA (n=9), IVIG (n=13), CPA (n=5), mitoxantrone (n=1), azathioprine (n=5), mycophenolate mofetil (n=2) and cyclosporin A (n=2). Patient who developed acquired anti-factor VIII inhibitor after ASCT was temporarily treated with rituximab. All pts have been treated with low-dose corticosteroids after ASCT as well. Early AEs included severe mucositis (n=7), sepsis (4), urinary tract infection (5), diarrhoea (8), haemorrhage (5). Late AEs included recurrent herpetic infection (1), arthralgia with rheumatoid factor positivity development (1), acquired anti-factor VIII inhibitor (1), glioblastoma multiforme (1). Mortality was 0%. Conclusion: Concluding from our eleven-year experience ASCT presents relatively safe and undoubtedly effective treatment for aggressive MS especially in young patients with still relapsing form of MS and disease duration up to fi ve years.
HIGH-DOSE IMMUNOABLATION AND STEM CELL TRANSPLANTATION IN MULTIPLE SCLEROSIS PATIENTS
DIFFERENCES IN MSCS IP-10 PRODUCTION BETWEEN MS PATIENTS AND HEALTHY DONORS
Alessandra Aldinucci, Benedetta Mazzanti*, Andrea Galante, Simone Dal Pozzo*, Riccardo Saccardi*, Luca Massacesi and Clara Ballerini Department Neurological Sciences, University of Florence, Italy *Department of Haematology, University of Florence, Italy Mesenchymal stem cells (MSCs) have been recently proposed as emerging cell therapy in autoimmune diseases, consistently with this notion several trials based on these cells have been already design. These applications might have a crucial impact in the future design of highly-targeted therapies in multiple sclerosis (MS). In our work, we demonstrate the possibility of isolation and expansion of MS isolated MSCs and we show that they signifi cantly differ from healthy donors (HD) ones for the production of IP-10 (p>0.0001). On the other hand, we do not evidence any differences between phenotypes, TLR expression profi le, in vitro immunomodulatory functions and micropinocytosis. Furthermore, we show that in MS MSCs there might be variability in the extent of IP-10 production during in vitro culture, suggesting a possible modulation of its ability. Taken together our data suggest that MSCs MS derived have similar features compared to HD ones, but we think that increased information and better understanding of MSC immunomodulatory activity is crucial for their future utilization in cell therapy. Furthermore, we think that increased production of IP-10 may represent a commune feature, shared between different cells, of severe MS. Therefore, we will analyse MSC IP-10 production in MS patients that undergo HSCT before and after transplantation, to verify if IP-10 production is modifi ed when infl ammatory phase of the disease is switched off. Bone marrow (BM) mesenchymal stem cells (MSCs) have been extensively studied for their immunoregulatory properties and there is wide agreement saying that they inhibit in vitro T cell proliferation, dendritic cell (DC) immunogenic ability and that they can in vivo ameliorate autoimmune diseases such as experimental allergic encephalomyelitis (EAE). During short term interactions MSCs induce a transformation in active DCs shifting their function into tolerance, without altering their phenotype. In our work we focused on MSC/ DC interactions during DC activation. Here we show that cell-cell contact is fundamental in MSC mediated induction of tolerogeneic DCs and we show for the fi rst time that MSC treated DCs were no more able to form active immune synapses. Moreover, treated DCs retain endocytic activity and maintain podosome like structures, "frozen" in an immature condition that may correlate with contact induced cytoskeleton rearrangement, as expression data confi rm. We describe a novel mechanism that may be crucial for in vivo generation of tolerogeneic DCs. We believe that to manipulate DCs with MSCs in order to promote tolerance may be a strategy to treat autoimmune diseases, but the possibility to use MSC transplantation as therapeutic tool depends on a wide comprehension of interactions that determine MSC mediated immunosuppression.
MSCS SHIFT DCS FROM IMMUNOGENIC TO
IMMUNOHISTOCHEMETRY ANALYSIS OF BONE MARROW BIOPSIES IN MULTIPLE SCLEROSIS PATIENTS UNDERGOING AUTOLOGOUS BONE MARROW TRANSPLANTATION
I. Donnini, V. Carrai, R. Saccardi, R. Alterini, G. Rotunno, S. Guidi, M. Di Gioia, A. Bosi Haematology Unit, AOU Careggi, Florence, Italy Introduction: Multiple Sclerosis (MS) is an immune-mediated disease of the central nervous system (CNS) determining demyelization and progressive neuro-degeneration. Genetic and environmental factors are believed to induce an aberrant immune reaction by auto reactive T cells myelin-specifi c CD4+ T helper cells type 1 (Th1) selectively striking oligodendrocytes that enter the CNS and attack myelin around axons. Chronic infl ammation and axonal injury result in a degeneration of tracts, gliosis and brain atrophy. Cytometric analysis using combinations of antigens has been performed for decades in MS, starting with the fi rst application of anti-CD4 and anti-CD8 antibodies that highlighted a reduced CD4/CD8 ratio in peripheral blood of MS patients. Furthermore, few data are available by bone marrow examination of the immunological profi le of MS patients. Materials and Methods: We analyzed BM biopsies in 13 patients undergoing autologous bone marrow transplantation (ABMT) in our Centre for MS. BM biopsies were collected before stem cells mobilisation with cyclophosphamide and compared with 5 bone marrow biopsies from adult with diagnosis of lymphoma without any evidence of marrow involvement. The main clinical features of the patients were the following: 8 were affected by Secondary Progressive MS, 5 by Relapsing Remitting MS. Median EDSS baseline was 5,6 (range 4 -7). Two patients was MRI Gadolinium+ before ABMT. All patients received prior therapies (Interferon, Azathioprine, Mitoxantrone, Cyclophosphamide, Steroids). To evaluate the immunological profi le, we tested the following monoclonal antibodies: CD3, CD4, CD8, CD20, CD45LCA. We also analyzed MMP9, that play a key role in the pathogenesis of MS, especially in neuro-infl ammation and blood-brain barrier disruption. Antibodies expression was evaluated as percentage of positive cells in a total of eight consecutive areas at 400 × magnifi cation. Results: All patients showed a mean cellularity of 40% (range 15-55%). We detected a normal cellularity according their age (range 22-55 years) only in 6 patients. The percentage value of B lymphocytes in MS patients was the half of the controls (4% vs. 8%). Patients expressed about 2% of T lymphocyte, which was similar to controls. Immunohistochemical staining showed a CD4/CD8 ratio 1,5/1, comparable to the controls. In bone marrow biopsies of MS patients, the mean expression of CD45 was 8%, whereas in normal biopsies was 20%. In all cases the expression of MMP9 was slightly higher than controls, with a median rate of 7% (range 1-15%) in patients vs. 5% (range 1-10%) in controls. Discussion: We demonstrated that patient with MS showed a reduction of bone marrow cellularity age-related, probably in relation to previous therapies. Bone marrow T immunological profi le of patients was similar to controls (2% in both groups), whereas CD20 and CD45LCA expression was double in controls. Regarding MMP9, in our study we have observed an increased expression in bone marrow of MS patients. Background: Autologous stem cell transplantation (ASCT) has been performed for aggressive Multiple Sclerosis (MS) with raising frequency. Various conditioning regimens have been used until now and none have been accepted as a standard for effi cacy and low toxicity. In our study, we evaluated a conditioning regimen (Thiotepa and Cyclophosphamide) previously untested in MS, in order to assess safety and effi cacy in aggressive forms of MS. Methods: From December 2005 to October 2007, 9 patients affected by MS, unresponsive to conventional therapies, with elevated infl ammatory disease activity, underwent ASCT in our institution. Five patients had a relapsing-remitting, 3 a secondary progressive and 1 an hyper-acute MS. Patients had a median of 26 years, 6 (range 2.5-8) points in EDSS disability score and median 15 enhancing lesions (range 1-67) on MRI before ASCT, with a median of 2 relapses in the 2 years before ASCT. Autologous hematopoietic stem cells were mobilized with Cyclophosphamide 4 gr/mq at day 0 followed by granulocyte colony stimulating factor 5 mcg/Kg/day from day +2 to stem cell harvest. Harvest was not manipulated before cryopreservation. The conditioning regimen before ASCT consisted of Thiotepa 5 mg/Kg bid on day -5 and Cyclophosphamide 50 mg/Kg on days -3 and -2. The median follow-up was 39.6 months. Results: Mobilization was successful in all cases, with a median of 12.91 × 10 6 collected and 5.7 × 10 6 infused CD34+cells/Kg. Hematopoietic recovery was documented safely in 9/9 patients, with a median of 10 days for neutrophil and platelet engraftment. The median time of hospitalization was 24 days. Six patients developed febrile neutropenia, lasting a median of 4.5 days. There were no serious adverse events. All patients are alive: seven patients are stable or improved at the last follow-up: 5 improved EDSS by at least 0.5 points, 2 are stable. Relapses were observed in 5 patients (4 at 1 year, 1 at 2 years after ASCT) with complete recovery after steroids. The confi rmed progression free survival is 88.8%, the disease activity free survival is 33%. A signifi cant reduction by the 86% of the annualized relapse rate and 84% of the enhancing lesions occurred. Conclusions: High-dose immunosuppressive therapy with Thiotepa and Cyclophosphamide followed by ASCT reduced disease activity and disability progression of aggressive MS with a safe profi le and low toxicities. Larger number of patients will be necessary to establish the value of this regimen in contributing to long-term disease remissions. Sporadic reports are available on Allo-HSCT in patients with neuroimmunological Ads. Here we report the experience on Allo-HSCT in a patient (pt) affected by severe Optic Neuromyelitis (NMO) associated with aquaporin-4 (AQP4) antibodies, with severe relapsing myelitis.
THIOTEPA-CYCLOPHOSPHAMIDE HIGH-DOSE IMMUNOSUPPRESSIVE THERAPY WITH AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION IN AGGRESSIVE FORMS OF MULTIPLE SCLEROSIS
ALLOGENEIC HAEMATOPOIETIC STEM CELL
Material and Methods:
The pt is a 28 years old man, who underwent HLA identical sibling Allo-HSCT for severe NMO, characterized by relapsing myelitis unresponsive to several treatments (steroids, Cyclophosphamide, Plasma Exchange, Rituximab, Thiotepa/Cyclophosphamide based Autologous HSCT), positive for aquaporin-4 (AQP4) antibodies. At preAllo-HSCT evaluation, pt showed 6 points in EDSS disability score with paraparesis, thoracic spinal cord lesion (D4-D8) on MRI and no AQP4 antibodies (recent therapy with high dose steroids and plasma exchange); 3 severe relapses occurred in the previous year. Results: The pt received a Treosulfan-Fludarabine based myeloablative conditioning regimen, consisting of Fludarabine i.v. 30 mg/m 2 /d day -6 to -2,Treosulfan i.v. 14 g/m 2 /d day -6 to -4, Rituximab i.v. 375 mg/mq day -1. The graft source was peripheral blood stem cells. At day 0 he received 5.98 × 10 6 infused CD34+cells/Kg. The prophylaxis for graft-versus-host disease (GvHD) was based on ATG-Fresenius i.v. 10 mg/kg day -4 to -2 and standard cyclosporine plus short course methotrexate. Hematopoietic recovery required 21 days for neutrophil and 6 days for platelet engraftment. During hospitalization the pt developed febrile neutropenia solved with antibiotics and a CMV reactivation responsive to Ganciclovir iv. Twelve days after Allo-HSCT a transient neurologic worsening occurred (paraparesis and MRI enhancing lesion on dorsal spinal cord), rapidly solved with high dose steroids. There were no major adverse events. Three months after transplantation patient developed a transient grade I GvHD (skin grade I, no liver-gut involvement) not treated, and an episode of cholecystitis treated with antibiotics. At 30 days after Allo-HSCT pt showed 7.0 points in EDSS score, a chimerism > 95% donor on STR analysis. At 60 days after Allo-HSCT pt showed 6.0 points in EDSS score, absence of AQP4 antibodies and a chimerism > 95% donor on STR analysis. At 100 days after Allo-HSCT he presented 5.0 points in EDSS score, absence of AQP4 antibodies, improvement of thoracic lesion without new enhancing lesions on MRI and a chimerism > 95% donor on STR analysis. Conclusions: These fi ndings suggest that Allo-HSCT may be benefi cial in patients who have an aggressive AD, reducing disease activity and arrest the disability progression, with a safety profi le and low toxicities.
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HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR SEVERE AUTOIMMUNE DISEASES (SADs). UPDATE OF A SINGLE -CENTER EXPERIENCE.
F. Gualandi, B. Bruno, S. Bregante, A. Dominietto, MT. van Lint, A. Uccelli, E. Capello, GL. Mancardi, A. Bacigalupo and AM. Marmont Genoa University Hospital, Genoa, Italy Starting from 1996, 50 patients with SADs were treated with highdose immuno-suppression (HDIS) in Genoa. Of these, 2 patients with SLE received a repeat mobilization (CY 4g/sm) because of initial poor harvest, and attained CR without proceeding to autologous stem cell transplantation (ASCT); 1 patient with SLE renal involvement received mobilization with CY 750 mg; 1 patient with MS and 1with SSc received mobilization alone because of harvest failure. Of the other patients 39 received ASCT, 4 received allogeneic SCT (2 after ASCT), 1 syngeneic and 1 a second ASCT for MS-relapse. One patient with severe pulmonary scleroderma died after mobilization, 1 with MS died 70 days after ASCT because of thromboembolic complications, and 1 patient with CIDP died 30 days post ASCT because of pneumonia. Twenty-four patients with MS were treated with ASCT and achieved total regression of Gd-enhancing CNS lesions, and 1 -2 degrees of improvement on EDSS scale: 1 patient relapsed 5 years after ASCT and underwent 2nd ASCT last month. Both only mobilized and auto-transplanted SLE patients achieved complete clinical remission (SLEDAI) and signifi cant reduction of biomarkers. Allogeneic transplants were performed for patients (Behcet's, Evans, PWCA and SLE) with very severe morbidity. One patient with severe RA received a syngeneic transplant, had a fall of anti-cyclic citrulline antibodies, but relapsed clinically 3 months later. Our experience indicates that ASCT, potentiated by prior stem cell mobilization with 4g/sm CY has a powerful remitting effect in SADs. More intense conditioning regimens have resulted in longer and better remissions, at the expense of a greater toxicity. Immunological cure was not achieved, and the so-called immune re-education is still being discussed. Prospective randomized clinical studies have been launched by the EBMT to establish the value of ASCT versus the best available non-transplant therapies. Allogeneic transplants have been often followed by relapses in spite of complete donor chimerism.
